RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Perspective Therapeutics - Stock

Perspective Therapeutics P/E 2024

Perspective Therapeutics P/E

-5.73

Ticker

CATX

ISIN

US46489V1044

WKN

A0MQNM

As of Jun 17, 2024, Perspective Therapeutics's P/E ratio was -5.73, a 88.49% change from the -3.04 P/E ratio recorded in the previous year.

The Perspective Therapeutics P/E history

Perspective Therapeutics Aktienanalyse

What does Perspective Therapeutics do?

The company IsoRay Inc is a leading global company in the field of brachytherapy and specializes in the development of novel medical devices for the treatment of cancer. The company's history dates back to the 1980s when it was founded by a team of doctors and scientists. IsoRay Inc's business model is based on the research, development, and manufacturing of medical products used in the treatment of cancer. Brachytherapy is a particularly important focus. This involves a treatment method where radioactive seeds or sources are directly implanted into the tumor. The radiation destroys the cancer cells without damaging the surrounding tissue. IsoRay Inc's product range includes a variety of medical devices and accessories for conducting brachytherapy procedures. The company specializes in the development of high-tech products that enable precise and effective radiation therapy. This includes, for example, radioactive seeds that are directly implanted into the tumor or apparatuses that can selectively use radiation in specific structures of the body. A special focus of IsoRay Inc is computer-assisted planning of brachytherapy treatments. The tumor is precisely measured and the radiation sources are individually customized based on the data to achieve an optimal radiation dose. This planning is done using modern software and is an important factor for the successful treatment of cancer. In addition to research and development of medical products, IsoRay Inc also encompasses the production and distribution of these products. The company operates in more than 30 countries worldwide and collaborates closely with numerous clinics and practices to research and improve new technologies in the field of radiation therapy. One of IsoRay Inc's most well-known products is the "Cesium-131 Brachytherapy seed." This radioactive seed is particularly small and therefore ideal for targeted radiation therapy of tumors. It is used in almost all clinical areas worldwide and is considered particularly safe and effective. Other products of the company include the "Gladius™ Applicator Needle," a device for precise placement of radiation sources in tumors, as well as "Intraoperative Application Systems" that enable effective radiation therapy during surgery. Overall, IsoRay Inc is considered an innovative and successful company in the field of brachytherapy and radiation therapy. The constant development and improvement of its own products is a key factor for the company's success. High quality and close collaboration with research and practice are central to its operations. Perspective Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Perspective Therapeutics's P/E Ratio

The Price to Earnings (P/E) Ratio of Perspective Therapeutics is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Perspective Therapeutics's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Perspective Therapeutics is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Perspective Therapeutics’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Perspective Therapeutics Stock

What is the price-to-earnings ratio of Perspective Therapeutics?

The price-earnings ratio of Perspective Therapeutics is currently -5.73.

How has the price-earnings ratio of Perspective Therapeutics changed compared to last year?

The price-to-earnings ratio of Perspective Therapeutics has increased by 88.49% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Perspective Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of Perspective Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of Perspective Therapeutics affect the company?

An increase in the price-earnings ratio of Perspective Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Perspective Therapeutics affect the company?

A decrease in the price-earnings ratio of Perspective Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Perspective Therapeutics?

Some factors that influence the price-earnings ratio of Perspective Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Perspective Therapeutics pay?

Over the past 12 months, Perspective Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Perspective Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Perspective Therapeutics?

The current dividend yield of Perspective Therapeutics is .

When does Perspective Therapeutics pay dividends?

Perspective Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Perspective Therapeutics?

Perspective Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Perspective Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Perspective Therapeutics located?

Perspective Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Perspective Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Perspective Therapeutics from 6/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/17/2024.

When did Perspective Therapeutics pay the last dividend?

The last dividend was paid out on 6/17/2024.

What was the dividend of Perspective Therapeutics in the year 2023?

In the year 2023, Perspective Therapeutics distributed 0 USD as dividends.

In which currency does Perspective Therapeutics pay out the dividend?

The dividends of Perspective Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Perspective Therapeutics

Our stock analysis for Perspective Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Perspective Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.